Tuberous sclerosis complex (TSC) is a tumor predisposition syndrome with significant renal cystic and solid tumor disease. While the most common renal tumor in TSC, the angiomyolipoma, exhibits a loss of heterozygosity associated with disease, we have discovered that the renal cystic epithelium is composed of type A intercalated cells that have an intact Tsc gene that have been induced to exhibit Tsc-mutant disease phenotype. This mechanism appears to be different than that for ADPKD. The murine models described here closely resemble the human disease and both appear to be mTORC1 inhibitor responsive. The induction signaling driving cystogenesis may be mediated by extracellular vesicle trafficking.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344348PMC
http://dx.doi.org/10.14814/phy2.13983DOI Listing

Publication Analysis

Top Keywords

tuberous sclerosis
8
sclerosis complex
8
renal cystic
8
complex exhibits
4
renal
4
exhibits renal
4
renal cystogenic
4
cystogenic mechanism
4
mechanism tuberous
4
complex tsc
4

Similar Publications

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder affecting multiple organ systems, with a prevalence of 1:6,760-1:13,520 live births in Germany. On the molecular level, TSC is caused by heterozygous loss-of-function variants in either of the genes TSC1 or TSC2, encoding the Tuberin-Hamartin complex, which acts as a critical upstream suppressor of the mammalian target of rapamycin (mTOR), a key signaling pathway controlling cellular growth and metabolism. Despite the therapeutic success of mTOR inhibition in treating TSC-associated manifestations, studies with mTOR inhibitors in children with TSC above two years of age have failed to demonstrate beneficial effects on disease-related neuropsychological deficits.

View Article and Find Full Text PDF

A 55-year-old man with tuberous sclerosis complex (TSC) was diagnosed with left renal angiomyolipoma (AML), a group of perivascular epithelioid cell tumors called PEComas. He had received the mTOR inhibitor everolimus, which resulted in a complete response. However, a left renal mass relapsed in two years, followed by the occurrence of a hepatic mass five months later.

View Article and Find Full Text PDF
Article Synopsis
  • There is a significant sex bias in autism spectrum disorder (ASD), with 80% of cases diagnosed in males, making it challenging to uncover the biological reasons behind this difference.
  • Loss of function mutations leading to dysregulated mTORC1 signaling are prevalent in individuals with tuberous sclerosis (TSC), and over 50% of those with TSC are also diagnosed with ASD, indicating a strong genetic link.
  • In experiments with mice, it was found that while motor coordination deficits are similar in both male and female mice, social interaction impairments are significantly worse in males, suggesting that certain behavioral issues in ASD may vary based on sex.
View Article and Find Full Text PDF

Background/aim: Lymphangioleiomyomatosis (LAM) belongs to the perivascular epithelioid cell tumor (PEComa) family. The relationship between LAM and tuberous sclerosis complex (TSC) is of particular concern in a subset of women with clinically occult LAM involving the pelvic lymph nodes. This study aimed to investigate the clinicopathological features of incidental nodal LAM detected during the surgical staging of gynecological tumors.

View Article and Find Full Text PDF

Introduction: Hereditary bleeding disorders stem from the absence or insufficient levels of particular clotting proteins, essential for facilitating coagulation in the clotting cascade. Among the most prevalent are hemophilia A (deficiency of Factor VIII), hemophilia B (deficiency of Factor IX), and von Willebrand disease. Management of pharmacoresistant epilepsy is more difficult in a patient with bleeding disorder due to increased risk of bleeding during surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!